中国癌症杂志 ›› 2013, Vol. 23 ›› Issue (11): 880-884.doi: 10.3969/j.issn.1007-3969.2013.11.005

• 论著 • 上一篇    下一篇

肝细胞癌组织中高尔基体糖蛋白73和分泌型聚集素的表达及其相关性分析

曹茜,古丽比也•沙比尔,杨颖,肖蕾,毛睿,张瑞丽,张华,包永星   

  1. 新疆医科大学第一附属医院肿瘤中心,新疆 乌鲁木齐 830054
  • 出版日期:2013-11-25 发布日期:2014-02-18
  • 通信作者: 包永星 E-mail:baoyx@vip.sina.com
  • 基金资助:

    乌鲁木齐市科学技术计划感染与肿瘤重点实验室(NoH111313001)
    吴阶平基金会临床研究课题(No320.6799.1138)

    新疆医科大学第一附属医院科研专项基金(No2012YFY07)

Expression of Golgi glycoprotein 73 and secreted Clusterin in hepatocellular carcinoma

CAO Qian,SHABIER Gulibiye,YANG Ying,XIAO Lei,MAO Rui,ZHANG Rui-li,ZHANG Hua,BAO Yong-xing   

  1. Tumor Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi Xinjiang 830054, China
  • Published:2013-11-25 Online:2014-02-18
  • Contact: BAO Yong-xing E-mail: baoyx@vip.sina.com

摘要:

背景与目的:肝细胞癌(hepatocellular carcinomaHCC)是一种具有高度侵袭、转移性的常见恶性肿瘤,预后极差。因此,研究肝癌侵袭的机制,寻找有效的干预靶点显得尤为重要。一些研究提示分泌型聚集素(secreted ClusterinsCLU)和高尔基体糖蛋白73(Golgi glycoprotein 73GP73)在肿瘤发生、发展及侵袭、转移过程中起重要作用,且两者具有结构和功能上的相似性。本研究旨在探讨GP73sCLUHCC中的表达及其与临床病理特征和预后之间的关系。方法:收集新疆医科大学第一附属医院75HCC患者癌组织及癌旁正常肝组织标本,采用免疫组化(EnVision二步法)检测HCC组织中GP73sCLU的表达水平;并与癌旁正常肝组织相比较;Spearman等级相关分析GP73sCLU在肝癌中表达的关系;研究GP73sCLU表达水平与HCC临床病理特征及预后的关系。结果:GP73sCLUHCC中阳性表达率分别为72%88%,癌旁正常肝组织的阳性表达率均为4%GP73HCC和正常肝组织中阳性表达差异有统计学意义(χ2=73.60P<0.05)sCLUHCC和正常肝组织中阳性表达差异有统计学意义(χ2=207.94P<0.05)Spearman等级相关分析提示,HCC组织中,GP73sCLU蛋白表达呈正相关(r=0.405P<0.05)GP73sCLUHCC中表达水平与肿瘤的Edmondson病理分级、TNM分期及血管侵犯相关(P<0.05),而与患者的性别、年龄、HBsAg、合并肝硬化、AFP值、门静脉癌栓、肿瘤数目无相关性(P>0.05)GP73表达与患者生存期有关,而sCLU表达与患者生存期无关。结论:GP73sCLU在肝癌中有较高的阳性率,且GP73sCLU表达呈正相关,GP73sCLU可能与HCC的侵袭性等生物行为密切相关,检测其表达将有助于评价患者预后。

关键词: 肝细胞癌, 高尔基体糖蛋白73, 分泌型聚集素, 侵袭, 预后

Abstract:

Background and purpose: Hepatocellular carcinoma (HCC) is a common cancer with poor prognosis. The main reason leading to the poor prognosis of HCC is the highly invasive and metastatic ability. Therefore, trying to know the mechanism of HCC invasion and getting an effective interventions target is very important. Some studies suggest that secreted clusterin (sCLU) and Golgi glycoprotein 73 (GP73) played important roles in the development of tumour process, and both of them have structural and functional similarities. The aim of the article was to investigate the expression of GP73 and sCLU in HCC and their relationship with the clinicopathological features and the prognosis, and finally to evaluate the value of them. Methods: Seventy-five cases of HCC were collected. Immunohistochemistry (IHC) was used to determine the expression of GP73 and sCLU in HCC and normal liver tissues. Spearman rank was used to analyze the correlation between GP73 and sCLU in HCC. The relationship of GP73 and sCLU expression with the clinicopathological features and the prognosis was investigated. Results: The positive rates of GP73 and sCLU in HCC were 72% (54/75) and 88% (66/75) respectively; but in normal liver tissues, it was 4% (3/75). GP73-positive rate in HCC was higher than that of the normal liver tissues (χ2=73.60, P<0.05). sCLU-positive rate in HCC was also higher than that of the normal liver tissues (χ2=207.94, P<0.05). GP73 expression was positively correlated with sCLU expression in HCC (r=0.405, P<0.05). GP73 and sCLU were associated with clinicopathological features including tumor differentiation, TNM stage and vascular invasion (P<0.05); GP73 and sCLU had no correlation with the patients gender, age, HBsAg, cirrhosis, AFP value, portal vein thrombosis and tumor numbers (P>0.05). GP73 was associated with survival but not sCLU. Conclusion: GP73 and sCLU have higher positive rates in HCC and GP73 is positively correlated with sCLU. The expression of GP73 and sCLU are probably closely related with the invasion of HCC, which can help evaluate the prognosis of the patients.

Key words: Hepatocellular carcinoma, Golgi glycoprotein 73, Secreted Clusterin, Invasion, Prognosis